Skip to main content
. 2023 Jan 11;13(1):212. doi: 10.3390/life13010212

Table 2.

Clinical, functional, and HRCT characteristics of ILD patients without PF and with PF and PPF.

Value ILD without PF ILD with PF ILD with PPF p # p ##
Number, n 166 104 62
Age, years 55 (42;65) 64 (55;70) 64 (56;73) <0.001 0.71
Male, n (%) 59 (35.5) 53 (51.0) 36 (58.1) 0.01 0.32
Symptoms
Dyspnea, n (%) 113 (68.1) 100 (96.2) 62 (100.0) <0.001 0.96
mMRC dyspnea, points 2 (1;2) 3 (2;3) 3 (2;3) <0.001 0.79
Cough, n (%) 120 (72.3) 97 (93.3) 59 (95.2) <0.001 0.91
Weight loss, n (%) 28 (16.8) 33 (31.7) 27 (43.5) 0.004 0.10
Clubbing, n (%) 6 (3.6) 23 (22.1) 20 (32.2) <0.001 0.10
Velcro crackles, n (%) 31 (18.6) 84 (80.8) 53 (85.5) <0.001 0.13
Functional characteristics
SpO2, % 97 (95;98) 95 (92;97) 94 (92;96) <0.001 0.31
FVC, % predicted 88 (73;101) 69 (58;87) 63 (52;76) <0.001 0.08
HRCT patterns
Honeycombing, n (%) 0 57 (54.8) 37 (59.7) <0.001 0.74
Traction bronchiectasis, n (%) 0 69 (63.5) 43 (69.4) <0.001 0.67
Reticular changes, n (%) 75 (45.2) 99 (95.2) 59 (95.2) <0.001 0.96
Ground-glass opacity, n (%) 58 (34.9) 40 (38.5) 23 (37.1) 0.56 0.93
Consolidation, n (%) 51 (30.7) 13 (12.5) 9 (14.5) <0.001 0.89
Basal predominance, n (%) 28 (16.9) 63 (60.6) 39 (62.9) <0.001 0.88
Course and outcome
Time from the onset of symptoms to diagnosis, months 6 (2;24) 24 (7;48) 30 (12;40) <0.001 0.88
Time from the first symptom to death, months 47 (26;65) 48 (27;72) 40 (21;62) 0.62 0.55
Death, n (%) 19 (11.4) 47 (45.2) 37 (59.8) <0.001 0.05

ILD—interstitial lung diseases; PF—pulmonary fibrosis; PPF—progressive pulmonary fibrosis; mMRC—modified Medical Research Council; SpO2—oxygen saturation of the blood; FVC—forced vital capacity; HRCT—high-resolution computed tomography. # p values compare ILD without PF and with PF. ## p values compare ILD with PF and with PPF.